Vor looks to answer the Car-T question
Can the company add a Car-T string to its stem cell transplant bow?
J&J catches its menin rivals
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
Kura’s Komet fizzles
The company heralds a pivotal win with its menin inhibitor, but investors want to see data.
AstraZeneca doubles down on GPC3
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
ASH 2024 – J&J mounts its first-line menin challenge
The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.
